
A randomized clinical trial of 399 adults found that fluvoxamine reduced long COVID-related fatigue and improved quality of life versus placebo. The results position a low-cost, widely available antidepressant as a potential treatment option for one of long COVID’s most disabling symptoms.
9:55 PMScienceDaily